Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?

Homaira, Nusrat2026-09-102026-09-102024-03-27Homaira N. Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants? Transl Pediatr 2024;13(3):525-529. doi: 10.21037/tp-23-534222443362-s2.0-85188955395https://hdl.handle.net/10361/29833525 - 529en-USInfantsMonoclonal antibodyNirsevimabRespiratory syncytial virus (RSV)Respiratory syncytial virusRespiratory syncytial virus.Children--Diseases.Infants--Diseases.Will nirsevimab be the holy grail for prevention of respiratory syncytial virus lower respiratory tract infections in infants?Article10.21037/tp-23-534